Is Protara Therapeutics, Inc. (TARA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.4% / 30% | 53.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.4% / 33% | 53.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.5% / 33% | 93.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.4% / 33% | 53.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.5% / 33% | 93.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -31.6% | |
| Return on Assets (ROA) | -20.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$56M |
| Free Cash Flow | -$56M |
| Total Debt | $3M |
| Debt-to-Equity | 1.7 |
| Current Ratio | 14.6 |
| Total Assets | $209M |
Price & Trading
| Last Close | $5.19 |
| 50-Day MA | $6.06 |
| 200-Day MA | $4.77 |
| Avg Volume | 1.1M |
| Beta | 1.4 |
|
52-Week Range
$2.77
| |
About Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Protara Therapeutics, Inc. (TARA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Protara Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Protara Therapeutics, Inc.'s debt ratio?
Protara Therapeutics, Inc.'s debt ratio is 1.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are Protara Therapeutics, Inc.'s key financial metrics?
Protara Therapeutics, Inc. has a market capitalization of $267M. Return on equity stands at -31.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.